CClinicalTrials.gg
RecruitingNCT05565833Updated May 8, 2024

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

A Phase 2 interventional study of SHUTi OASIS and Patient Education in Insomnia, Cognitive Dysfunction and Mild Cognitive Impairment, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by University of Virginia · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 7 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This randomized controlled trial will evaluate the impact of an Internet-delivered cognitive behavioral therapy for insomnia (CBT-I) intervention on sleep and the extent to which it contributes to cognitive health in individuals with mild cognitive impairment. Participants with insomnia who meet the study criteria for mild cognitive impairment will be recruited to determine the effects of the CBT-I intervention compared to a patient education condition on sleep and cognition. Internet-based recruitment methods will be used, and outcomes include sleep variables, daytime variables, and cognitive status.

Read the detailed description

This randomized controlled trial will evaluate the impact of an Internet-delivered cognitive behavioral therapy for insomnia (CBT-I) intervention on sleep and the extent to which it contributes to cognitive health in individuals with mild cognitive impairment. Participants with insomnia who meet the study criteria for mild cognitive impairment will be recruited to determine the effects of the CBT-I intervention compared to patient education (PE) control condition on sleep and cognition. Internet-based recruitment methods will be used, and outcomes include sleep variables (reduced overall insomnia severity and wake after sleep onset), daytime variables (reduced levels of fatigue, improved quality of life, and improved mood), and cognitive status (memory, attention/psychomotor speed, and executive functioning domains). Participants will complete a pre-assessment battery, which consists of an online cognitive test, an online questionnaire, and two weeks of sleep diaries. Once complete, participants will be randomized to either the Internet-based PE or CBT-I intervention. At the start of week nine, all participants will be instructed to complete the post-assessment battery (cognitive test, questionnaires, and diaries). After completing the post-assessment, participants will have continued access to their assigned online program throughout the study duration. This same assessment (cognitive test, questionnaires, and diaries) will be completed at 6, 12, 18, and 24 months.

02

Conditions studied

  • Insomnia
  • Cognitive Dysfunction
  • Mild Cognitive Impairment
  • Sleep Initiation and Maintenance Disorders
  • Sleep Disorders, Intrinsic
  • Dyssomnias
  • Sleep Wake Disorders
  • Nervous System Diseases
  • Alzheimer Disease

Keywords

  • Insomnia
  • Alzheimer's disease
  • Mild cognitive impairment
  • Cognitive behavioral therapy
03

In context

Alzheimer Disease

3,678 studies on the registry are indexed under Alzheimer Disease; 869 are open to participants now.

This study's planned enrollment of 144 is above the median of 70 across 2,805 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

University of Virginia is the lead sponsor of 653 studies on the registry; 134 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 41 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥ 65 years of age.
  • Able to speak and read English, and is a US resident.
  • Have access to any Internet-enabled device (computer, tablet, smartphone) and willing to be emailed about the study.
  • Sleep-onset insomnia and/or sleep maintenance insomnia symptoms
  • The sleep disturbance (or associated daytime fatigue) causes significant distress or impairment in social, occupational, or other areas of functioning over the past three months.
  • Cognitive impairment through study assessment.
  • Stable medication regimen unless medication is known to cause insomnia

Exclusion criteria

Exclusion Criteria:

  • Current psychological treatment for insomnia
  • Initiation of psychological or psychiatric treatment within the past three months
  • Current diagnosis of Huntington's or Parkinson's disease
  • Current treatment for hyperthyroidism
  • Currently undergoing chemotherapy
  • Presence of asthma or respiratory concerns with night treatment
  • Chronic pain treated with opioids
  • Not recovered from a brain tumor, injury, or infection
  • Epilepsy without stable treatment for at least 3 months
  • Irregular sleep schedule
  • Use of stimulating medications after 5pm or taken for less than 3 months
  • Psychotic or bipolar disorder
  • Moderate to high risk of suicide
  • Alcohol or drug abuse within the past year
  • Other untreated sleep disorders (e.g., obstructive sleep apnea)
  • Study screen for severe depression
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    SHUTi OASIS

    Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) for Older Adult Sufferers of Insomnia and Sleeplessness (OASIS) online intervention optimized for older adults. CBTi will be delivered online and metered out over time with each new core becoming available one week after the completion of the previous core. The intervention period is 9 weeks. They will spend 1-2 hours during the intervention period completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions on how to improve their sleep.

    Behavioral: SHUTi OASIS

  • Placebo comparator
    Patient Education Website

    Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.

    Other: Patient Education

Interventions

  • BehavioralSHUTi OASIS

    Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program

  • OtherPatient Education

    An educational website containing information on insomnia

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index

    Change in overall insomnia severity

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

Secondary outcomes

  1. Wake after sleep onset (WASO)

    Change in periods of wakefulness occurring after defined sleep onset as measured by daily sleep diaries over 10-14 day periods, measured in minutes, collected through sleep diary entries

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  2. Sleep onset latency (SOL)

    Change in length of time that it takes to transition from wakefulness to sleep, measured in minutes, collected through sleep diary entries

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  3. Multidimensional Fatigue Symptoms Inventory - Short Form

    Change in self-report measures of five dimensions of fatigue ( general fatigue, physical fatigue, emotional fatigue, mental fatigue, and vigor) measured using Multidimensional Fatigue Symptoms Inventory-Short Form. Total MFSI-SF scores range from 24 to 96, with a higher score indicating a higher fatigue level

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  4. Short Form-12 Health Survey (Quality of Life)

    The SF-12 Health Survey will be used to measure changes in physical and mental quality of life. Scores range from 0 to 100, with higher scores indicating better physical and mental health

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  5. Match to Sample Visual Search

    Changes in attention and processing speed will be measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB) Match to Sample Visual Search

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  6. Spatial Working Memory Test

    Changes in working memory and executive function will be measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Test

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  7. Paired Associates Learning

    Changes in episodic memory will be measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  8. Sleep Efficiency

    Amount of time spent asleep divided by the total time in bed

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

Other outcomes

  1. Insomnia Knowledge Scale

    Sleep knowledge and cognitive behavioral therapy for insomnia techniques; scores range from 0-10 and higher scores indicate greater insomnia knowledge

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  2. Center for Epidemiologic Studies Depression Scale (CES-D)

    Depression and anxiety are measured using the Center for Epidemiologic Studies Depression Scale (CES-D). Scores range from 0-60, where higher scores indicate greater likelihood of depression

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  3. Falls frequency

    Falls questionnaire including number and frequency of falls

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  4. Patient-Reported Outcomes Measurement Information System (PROMIS)

    Pain intensity and interference are measured using PROMIS Pain Intensity questions. On a scale of 0-100, a score of 50 is considered the mean/reference population, and higher scores indicate greater pain intensity.

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  5. Self-Efficacy Scale- Insomnia-Specific

    Global-, task-, and self-regulation self-efficacy changes are measured using Self-Efficacy Scale developed by Bouchard, Bastien \& Morin (2010) and includes 40 questions. Questions are answered using a scale from 0 (can't do at all) to 100 (absolutely certain can do), where higher scores indicate higher self-efficacy.

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

  6. Lawson's Instrumental Activities of Daily Living Scale

    Activities that allow an individual to live independently in a community. Score range from 0 (low function, dependent) to 8 (high function, independent).

    Time frame: Baseline, 9 weeks, 6 months, 12 months, 18 months, and 24 months

07

Study locations

1 of 1 sites recruiting
  • University of Virginia
    Charlottesville, Virginia 22908, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05565833
Lead sponsor
University of Virginia
Responsible party
Meghan Mattos (Assistant Professor of Nursing, University of Virginia) — Principal investigator
First posted
Oct 4, 2022
Start date
Feb 27, 2023
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
May 8, 2024

Study contacts

Meghan K Mattos, PhD, RN, CNL
Contact
ms2bv@virginia.edu
434-243-3936
Meghan K Mattos, PhD, RN, CNL
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion